ATE370229T1 - Ein verstärkter, durch viren vermittelter dna- transfer - Google Patents

Ein verstärkter, durch viren vermittelter dna- transfer

Info

Publication number: ATE370229T1
Authority: AT; Austria
Prior art keywords: cells; fibronectin; hematopoietic; mediated dna; dna transfer
Prior art date: 1994-03-25

Application number

AT95914912T

Other languages

English (en)

Inventor

David A Williams

Vikram P Patel

Original Assignee

Univ Indiana Res & Tech Corp

Univ Northwestern

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-03-25

Filing date

1995-03-27

Publication date

2007-09-15

1995-03-27 Application filed by Univ Indiana Res & Tech Corp, Univ Northwestern filed Critical Univ Indiana Res & Tech Corp

2007-09-15 Application granted granted Critical

2007-09-15 Publication of ATE370229T1 publication Critical patent/ATE370229T1/de

Links

102000016359 Fibronectins Human genes 0.000 abstract 4
108010067306 Fibronectins Proteins 0.000 abstract 4
210000004027 cell Anatomy 0.000 abstract 4
239000012634 fragment Substances 0.000 abstract 2
230000003394 haemopoietic effect Effects 0.000 abstract 2
210000003958 hematopoietic stem cell Anatomy 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
230000001177 retroviral effect Effects 0.000 abstract 2
230000001413 cellular effect Effects 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
238000001415 gene therapy Methods 0.000 abstract 1
230000000392 somatic effect Effects 0.000 abstract 1
230000026683 transduction Effects 0.000 abstract 1
238000010361 transduction Methods 0.000 abstract 1
241001430294 unidentified retrovirus Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Animal Behavior & Ethology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Public Health (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Environmental Sciences (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biodiversity & Conservation Biology (AREA)
Toxicology (AREA)
Animal Husbandry (AREA)
Oncology (AREA)
Diabetes (AREA)
Immunology (AREA)

AT95914912T 1994-03-25 1995-03-27 Ein verstärkter, durch viren vermittelter dna- transfer ATE370229T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/218,355 US5686278A (en)	1994-03-25	1994-03-25	Methods for enhanced retrovirus-mediated gene transfer

Publications (1)

Publication Number	Publication Date
ATE370229T1 true ATE370229T1 (de)	2007-09-15

Family

ID=22814775

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT95914912T ATE370229T1 (de)	1994-03-25	1995-03-27	Ein verstärkter, durch viren vermittelter dna- transfer

Country Status (13)

Country	Link
US (1)	US5686278A (de)
EP (2)	EP0752874B1 (de)
JP (4)	JP3411039B2 (de)
KR (2)	KR100506570B1 (de)
CN (3)	CN100567488C (de)
AT (1)	ATE370229T1 (de)
AU (1)	AU690667B2 (de)
CA (1)	CA2185712C (de)
DE (1)	DE69535560T2 (de)
ES (1)	ES2294781T3 (de)
RU (1)	RU2174846C2 (de)
TW (1)	TWI232884B (de)
WO (1)	WO1995026200A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9101680A (nl)	1991-10-04	1993-05-03	Tno	Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
US6506604B2 (en) *	1993-06-11	2003-01-14	Cell Genesys, Inc.	Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US6033907A (en) *	1995-09-29	2000-03-07	Indiana University Foundation	Enhanced virus-mediated DNA transfer
US7083979B1 (en) *	1994-03-25	2006-08-01	Indiana University Foundation	Methods for enhanced retroviral-mediated gene transfer
KR100506569B1 (ko) *	1995-09-29	2005-12-26	인디아나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	바이러스- 및 세포-결합 도메인을 갖는 분자를 사용하여 바이러스-매개된 dna 전달을 향상시키는 방법
CA2235629A1 (en) *	1995-11-13	1997-05-22	Takara Shuzo Co., Ltd.	Method for gene transfer into target cells with retrovirus
CA2279673A1 (en)	1995-12-15	1997-06-16	Enzo Therapeutics, Inc.	Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
CA2260325A1 (en) *	1996-07-10	1998-01-15	Takara Shuzo Co., Ltd.	Cell compositions
NZ337945A (en) *	1997-03-18	2001-10-26	Introgene B	Combining primate bone marrow cells with a recombinant retrovirus using a physical means to bring them into close physical contact
TWI239352B (en) *	1997-07-23	2005-09-11	Takara Bio Inc	Gene transfer method with the use of serum-free medium
ATE350482T1 (de) *	1998-07-01	2007-01-15	Takara Bio Inc	Gentransfermethoden
US6060317A (en) *	1998-08-11	2000-05-09	The United States Of America As Represented By The Department Of Health And Human Services	Method of transducing mammalian cells, and products related thereto
KR100674140B1 (ko) *	1999-03-23	2007-01-26	다카라 바이오 가부시키가이샤	유전자 치료제
US7261881B1 (en)	1999-05-20	2007-08-28	Yale University	Modulation of angiogenesis and wound healing
TWI317285B (en) *	2000-07-28	2009-11-21	Dainippon Sumitomo Pharma Co	New use and kit for remedies for cancer
US6627442B1 (en) *	2000-08-31	2003-09-30	Virxsys Corporation	Methods for stable transduction of cells with hiv-derived viral vectors
WO2003028768A1 (fr) *	2001-09-12	2003-04-10	Takara Bio Inc.	Traitements
DE602005027673D1 (de) *	2004-03-05	2011-06-09	Vegenics Pty Ltd	Materialien und verfahren für wachstumsfaktorbindende konstrukte
US7319015B2 (en) *	2004-03-16	2008-01-15	The Regents Of The University Of Michigan	Methods and compositions for using alveolar macrophage phospholipase A2
US7582442B2 (en)	2004-03-16	2009-09-01	The Regents Of The University Of Michigan	Methods and compositions for using aleveolar macrophage phospholipase A2
US20090233986A1 (en) *	2004-07-27	2009-09-17	Mount Sinai School Of Medicine	Methods and compositions for using sax2
US20070275874A1 (en) *	2004-09-03	2007-11-29	Yale University	Use of Leptin in Wound Healing
FI20050753A7 (fi)	2004-09-03	2006-03-04	Licentia Oy	Uudet peptidit
EP1795601B1 (de)	2004-09-29	2014-01-22	Takara Bio Inc.	Zelle zur produktion eines retrovirusvektors
JPWO2006082958A1 (ja)	2005-02-07	2008-06-26	タカラバイオ株式会社	レトロウイルスの保存方法
US7531523B2 (en)	2005-02-17	2009-05-12	Vertex Pharmaceuticals Incorporated	Sodium channel protein type III alpha-subunit splice variant
US8835177B2 (en)	2005-06-15	2014-09-16	Takara Bio Inc.	Method for transfer of gene into fat cell or progenitor fat cell
EP1921136B1 (de)	2005-08-16	2012-12-12	Takara Bio, Inc.	Nukleinsäure zur behandlung oder vorbeugung einer immunschwächevirusinfektion
US7972813B2 (en) *	2005-09-30	2011-07-05	Vertex Pharmaceuticals Incorporated	Tetrodotoxin-resistant sodium channel alpha subunit
US20080200408A1 (en) *	2005-09-30	2008-08-21	Mccormack Kenneth	Deletion mutants of tetrodotoxin-resistant sodium channel alpha subunit
CA2633468C (en)	2005-12-14	2014-02-18	Licentia Ltd	Novel neurotrophic factor protein and uses thereof
US20090214496A1 (en) *	2006-01-30	2009-08-27	Licentia Ltd.	Bmx/etk tyrosine kinase gene therapy materials and methods
DK2548578T3 (da)	2006-05-17	2014-10-06	Ludwig Inst Cancer Res	Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme
WO2008133137A1 (ja)	2007-04-20	2008-11-06	Takara Bio Inc.	遺伝子治療のためのベクター
FI20070808A0 (fi)	2007-10-25	2007-10-25	Mart Saarma	GDNF:n silmukointivariantit ja niiden käytöt
US20090196854A1 (en) *	2008-02-04	2009-08-06	Kytos Biosystems S.A.	Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
FI20080326A0 (fi)	2008-04-30	2008-04-30	Licentia Oy	Neurotroofinen tekijä MANF ja sen käytöt
WO2010002895A2 (en)	2008-06-30	2010-01-07	The Regents Of The University Of Michigan	Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
KR101043871B1 (ko) *	2008-08-18	2011-06-22	가톨릭대학교 산학협력단	동종 제대혈 혈청 또는 혈장을 사용하는 유전자 도입 방법
WO2010080032A2 (en) *	2009-01-09	2010-07-15	Stichting Het Nederlands Kanker Instituut	Bead-assisted viral transduction
US20120142109A1 (en)	2009-08-25	2012-06-07	Yoshinori Katayama	Method for producing t cell population under presence of retinoic acid
WO2012002452A1 (ja)	2010-06-30	2012-01-05	タカラバイオ株式会社	遺伝子導入方法
US9228206B2 (en)	2010-06-30	2016-01-05	Takara Bio Inc.	Method for gene transfer
EP2732029B1 (de)	2011-07-11	2019-01-16	FUJIFILM Cellular Dynamics, Inc.	Verfahren zur zellprogrammierung und genommanipulation
ES2642276T3 (es) *	2011-09-29	2017-11-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Vectores lentivirales pseudotipados con glicoproteínas de envoltura BaEV mutantes
JP6053688B2 (ja)	2011-10-07	2016-12-27	国立大学法人三重大学	キメラ抗原受容体
WO2013184209A1 (en)	2012-06-04	2013-12-12	Ludwig Institute For Cancer Research Ltd.	Mif for use in methods of treating subjects with a neurodegenerative disorder
WO2014191630A2 (en)	2013-05-28	2014-12-04	Helsingin Yliopisto	Non-human animal model encoding a non-functional manf gene
ES2845898T5 (en)	2014-08-26	2025-06-17	Univ Leland Stanford Junior	Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling
PL3194602T3 (pl) *	2014-09-18	2020-07-27	Université de Montréal	Związki i sposoby dla wzmocnienia przeniesienia wirusowego genu do ludzkich komórek krwiotwórczych
CA2994969A1 (en)	2015-08-06	2017-02-09	Dana-Farber Cancer Institute, Inc.	Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
EP3365453A2 (de)	2015-10-22	2018-08-29	Juno Therapeutics GmbH	Verfahren, kits, mittel und vorrichtungen zur transduktion
US11052111B2 (en)	2015-12-08	2021-07-06	Chimera Bioengineering, Inc.	Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
WO2017196175A1 (en)	2016-05-12	2017-11-16	Erasmus University Medical Center Rotterdam	A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium.
EP3858365B1 (de)	2016-09-01	2024-01-31	Chimera Bioengineering Inc.	Goldoptimierte car-t-zellen
EP3580212A4 (de)	2017-02-08	2021-03-17	Dana Farber Cancer Institute, Inc.	Regulierung von chimären antigenrezeptoren
US12077590B2 (en) *	2017-02-22	2024-09-03	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Bispecific antibody for cancer immunotherapy
NL2019517B1 (en)	2017-09-08	2019-03-19	Univ Erasmus Med Ct Rotterdam	New therapy for Pompe disease
WO2021070956A1 (ja)	2019-10-11	2021-04-15	タカラバイオ株式会社	ｓｉＲＮＡ発現ベクター
JP2023511024A (ja)	2019-12-30	2023-03-16	サン－ゴバンパフォーマンスプラスティックスコーポレイション	細胞形質導入のための容器及び方法
CN119470309B (zh) *	2025-01-08	2025-05-06	南京天纵易康生物科技股份有限公司	一种重组三型人源化胶原蛋白的细胞学检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5198423A (en) *	1989-05-26	1993-03-30	Takara Shuzo Co., Ltd.	Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
ATE348175T1 (de) *	1992-07-17	2007-01-15	Dana Farber Cancer Inst Inc	Method eder intrazellularen bindung von zielgerichteten molekülen

1994
- 1994-03-25 US US08/218,355 patent/US5686278A/en not_active Expired - Lifetime
1995
- 1995-03-27 EP EP95914912A patent/EP0752874B1/de not_active Expired - Lifetime
- 1995-03-27 DE DE69535560T patent/DE69535560T2/de not_active Expired - Lifetime
- 1995-03-27 CN CNB2004100905683A patent/CN100567488C/zh not_active Expired - Lifetime
- 1995-03-27 WO PCT/US1995/003817 patent/WO1995026200A1/en not_active Ceased
- 1995-03-27 JP JP52525795A patent/JP3411039B2/ja not_active Expired - Fee Related
- 1995-03-27 CN CN200410082654XA patent/CN1775946B/zh not_active Expired - Lifetime
- 1995-03-27 CA CA002185712A patent/CA2185712C/en not_active Expired - Lifetime
- 1995-03-27 AU AU21979/95A patent/AU690667B2/en not_active Expired
- 1995-03-27 KR KR10-2002-7006445A patent/KR100506570B1/ko not_active Expired - Lifetime
- 1995-03-27 EP EP07075458A patent/EP1862546A1/de not_active Ceased
- 1995-03-27 RU RU96119984/14A patent/RU2174846C2/ru active
- 1995-03-27 KR KR1019960705364A patent/KR100445712B1/ko not_active Expired - Lifetime
- 1995-03-27 AT AT95914912T patent/ATE370229T1/de not_active IP Right Cessation
- 1995-03-27 ES ES95914912T patent/ES2294781T3/es not_active Expired - Lifetime
- 1995-03-27 CN CNB951932683A patent/CN1177046C/zh not_active Expired - Lifetime
- 1995-06-05 TW TW091109773A patent/TWI232884B/zh not_active IP Right Cessation
2000
- 2000-10-25 JP JP2000326079A patent/JP2001169789A/ja active Pending
2002
- 2002-08-01 JP JP2002225109A patent/JP3934005B2/ja not_active Expired - Lifetime
- 2002-11-13 JP JP2002329696A patent/JP2003135086A/ja active Pending

Also Published As

Publication number	Publication date
KR20030097595A (ko)	2003-12-31
CN1775946A (zh)	2006-05-24
DE69535560D1 (de)	2007-09-27
CN1775946B (zh)	2010-11-10
CA2185712A1 (en)	1995-10-05
EP0752874A1 (de)	1997-01-15
MX9604240A (es)	1998-08-30
TWI232884B (en)	2005-05-21
RU2174846C2 (ru)	2001-10-20
WO1995026200A1 (en)	1995-10-05
AU690667B2 (en)	1998-04-30
KR100445712B1 (ko)	2004-11-26
EP0752874A4 (de)	1999-05-12
JP3411039B2 (ja)	2003-05-26
CN100567488C (zh)	2009-12-09
JP2001169789A (ja)	2001-06-26
DE69535560T2 (de)	2008-04-30
EP1862546A1 (de)	2007-12-05
CN1177046C (zh)	2004-11-24
JP3934005B2 (ja)	2007-06-20
ES2294781T3 (es)	2008-04-01
KR970702065A (ko)	1997-05-13
CA2185712C (en)	2002-10-22
CN1152875A (zh)	1997-06-25
CN1632116A (zh)	2005-06-29
EP0752874B1 (de)	2007-08-15
KR100506570B1 (ko)	2005-08-10
US5686278A (en)	1997-11-11
AU2197995A (en)	1995-10-17
JP2003135086A (ja)	2003-05-13
JPH09510874A (ja)	1997-11-04
JP2003111598A (ja)	2003-04-15

Legal Events

Date	Code	Title	Description
2008-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE370229T1 (de)	2007-09-15	Ein verstärkter, durch viren vermittelter dna- transfer
EP0873049A4 (de)	1998-12-02
AU4981101A (en)	2001-10-15	Subtilisin variants
PT900279E (pt)	2005-01-31	Processo melhorado de transformacao de plantas
PT1526172E (pt)	2011-09-01	Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo
UA42089C2 (uk)	2001-10-15	Протигрипозна вакцина на основі поверхневого антигену, спосіб її виробництва
DE50013610D1 (de)	2006-11-23	Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
ATE482267T1 (de)	2010-10-15	Tierzellen und verfahren für die replikation von influenza viren
FI870343A7 (fi)	1987-07-29	Menetelmä geenien ilmentämiseksi kasveissa, kasvien osissa ja kasvisoluviljelmissä sekä menetelmässä käytettävät DNA-fragmentit, plasmidit ja transformoidut mikro-organismit
EP1064308A4 (de)	2004-08-11	Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
WO2002006457A3 (en)	2002-10-17	Novel lipase genes
ATE526818T1 (de)	2011-10-15	Gentechnisch hergestellte wasserlinse
AU571128B2 (en)	1988-03-31	Expression of immunologically reactive aids viral protein
BR8108074A (pt)	1982-09-21	Sequencia de dna,plasmidio recombinante,ligadores de dna,cultura bacterial e processo para produzir taumatina
ES8608581A1 (es)	1986-07-16	Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
DK1334197T3 (da)	2011-04-04	Gær-afledt vaccine mod IPNV
ATE103989T1 (de)	1994-04-15	Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
ATE233321T1 (de)	2003-03-15	Verbesserungen in der herstellung von proteinen in wirtszellen
AU2002346803A1 (en)	2003-05-19	Genes encoding for carbon metabolism and energy-producing proteins
DE3671603D1 (de)	1990-07-05	Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
WO2002083896A3 (en)	2003-03-13	Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
DK628188A (da)	1989-06-24	Protein og fremgangsmaade til fremstilling deraf
ES8800350A1 (es)	1987-11-16	Procedimiento para preparar una cepa microbiana transformada mediante un plasmido recombinante.
BRPI0002694C1 (pt)	2021-05-25	processo de obtenção de vacina contra raiva em células vero, para uso humano
WO2001059139A3 (de)	2002-01-10	Ozon- und/oder pathogen-induzierbare genexpression in pflanzen